Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099242 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,040
- Enrollment target
NCT00099242 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,040 participants.
The verdict
NCT00099242, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,040 participants
- Enrollment target
Study Summary
The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.
Interventions
- DRUG rivastigmine transdermal patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,040 participants |
| Start Date | 2003-11 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00099242
The ClinicalTrials.gov registry entry for NCT00099242 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,040 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rivastigmine transdermal patch is the first listed.
NCT00099242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00099242 about?
NCT00099242 is a clinical study titled "Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease". The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.
What is the current status of trial NCT00099242?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,040 participants. The study started on 2003-11. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00099242?
The interventions under investigation include: rivastigmine transdermal patch (DRUG).
Who is sponsoring clinical trial NCT00099242?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.